Reuters logo
BRIEF-Concert Pharmaceuticals initiates CTP-543 phase 2 trial in alopecia areata
May 2, 2017 / 10:40 AM / 5 months ago

BRIEF-Concert Pharmaceuticals initiates CTP-543 phase 2 trial in alopecia areata

May 2 (Reuters) - Concert Pharmaceuticals Inc:

* Concert Pharmaceuticals initiates ctp-543 phase 2 trial in alopecia areata

* Concert Pharmaceuticals Inc - company expects to report topline data in Q1 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below